NVO Jun 2024 150.000 call
| Previous Close | 0.0700 |
| Open | 0.0300 |
| Bid | 0.0300 |
| Ask | 0.0500 |
| Strike | 150.00 |
| Expire Date | 2024-06-07 |
| Day's Range | 0.0100 - 0.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 30 |
GlobeNewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 3 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiate
PR NewswireNovo Nordisk launches national Wegovy® campaign, Power of Wegovy®
Novo Nordisk today launched The Power of Wegovy®, a new national campaign. The campaign aims to educate on the clinical data of Wegovy® (semaglutide) 2.4 mg injection and reflect the collective empowerment people living with obesity can feel when they don't have to manage their weight alone.
Investor's Business DailyS&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly, Novo Nordisk, Vertex Pharmaceuticals, Intuitive Surgical and Universal Health are all trading in or near buy zones. Medical stocks are often viewed as defensive growth stocks, because their growth is insulated from economic swings due to the government or insurance covering most of the costs. Eli Lilly is in a buy zone while weight-loss drug rival and fellow IBD Leaderboard member Novo Nordisk is setting up.
